Skip to main content

Table 3 Multivariate Cox’s proportional hazards regression model on combination therapy of EBMs

From: The impact of age on the implementation of evidence-based medications in patients with coronary artery disease and its prognostic significance: a retrospective cohort study

Medication

Age (years-old)

Combinations

< 60

60–75

≥75

All-cause death

 Model 0

1.00

1.00

1.00

 Model 1

0.11 (0.03–0.34)

0.15 (0.09–0.26)

0.17 (0.08–0.33)

 Model 2

0.06 (0.02–0.18)

0.12 (0.08–0.19)

0.15 (0.08–0.26)

 Model 3

0.10 (0.04–0.25)

0.08 (0.05–0.13)

0.15 (0.08–0.27)

CV death

 Model 0

1.00

1.00

1.00

 Model 1

0.07 (0.02–0.27)

0.10 (0.05–0.20)

0.10 (0.04–0.26)

 Model 2

0.04 (0.01–0.13)

0.07 (0.04–0.13)

0.10 (0.05–0.22)

 Model 3

0.04 (0.01–0.14)

0.07 (0.04–0.12)

0.08 (0.04–0.19)

  1. Adjusted factor: sex, history of hypertension, history of diabetes mellitus, and history of heart failure, history of dyslipidemia, smoking status, eGFR and hepatic enzymes. Model 0: no medication; model 1: prescribed 1 type of EBMs; model 2, prescribed 2 types of EBMs; model 3, prescribed all 3 types of EBMs. Three types of EBMs included: statin, beta-blockers, and RAAS inhibitors (ACEIs or ARBs). Abbreviations: EBMs: evidence-based medications, CAD: coronary artery disease, CI: confidence interval, CV death: cardiovascular death, HR: hazard ratio
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us